Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.41 |
| ▸ | CETP | P11597 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | PRKDC | P78527 | 1/20 | 0.40 |
| ▸ | YAP1 | P46937 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4333203 | 0.83 | MEN1 (0.40) | MEN1NPC1TP53TSHRRAB9A | |
| SCHEMBL4333723 | 0.81 | KDR (0.40) | MAPK14BRAFKDR | |
| SCHEMBL12503676 | 0.81 | YAP1 (0.46) | GPR119CETPBRAFKDRPIK3CA | |
| SCHEMBL4329061 | 0.81 | AXL (0.43) | GPR119CETPBRAFKDRPIK3CA | |
| SCHEMBL1892285 | 0.80 | YAP1 (0.45) | FAAHGPR119CETPBRAFKDR | |
| SCHEMBL13788582 | 0.79 | LMNA (0.48) | MEN1NPC1KMT2ABRAFKDR | |
| SCHEMBL4413188 | 0.77 | KDR (0.39) | MAPK14BRAFKDR | |
| SCHEMBL4327777 | 0.77 | BRAF (0.51) | BRAFKDR | |
| SCHEMBL4423786 | 0.77 | KDR (0.47) | NPC1RAB9ABRAFKDR | |
| SCHEMBL4328795 | 0.77 | SMN1; SMN2 (0.47) | MEN1KMT2ASMN1; SMN2MAPK14BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1682126-B1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF RAF KINASE | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2009-07-01 | — | — | EP | disclosed |
| US-7423150-B2 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | NOVARTIS AG (CH) | 2008-09-09 | — | — | US | disclosed |
| EP-1682126-A1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF RAF KINASE | CHIRON CORPORATION (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20050192287-A1 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | CHIRON CORPORATION (US) | 2005-09-01 | — | — | US | disclosed |
| WO-2005037273-A1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF RAF KINASE | CHIRON CORPORATION (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192287-A1 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | BRAF, RAF1, ARAF | MEN1 2406/4885NPC1 4051/4885TP53 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.